Breast Cancer News

Piqray® approved for the treatment of postmenopausal women with breast cancer (May 29, 2019)

The US Food and Drug Administration (FDA) has approved Piqray® (alpelisib, formerly BYL719) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor-2... Continue Reading

Subcutaneous Herceptin Effective Option for Women With HER2-positive Breast Cancer (May 6, 2019)

One year of IV Herceptin (trastuzumab) is the standard of care for women with HER2-positive early stage breast cancer (ESBC). Doctors from Germany have confirmed that Herceptin can safely be administered subcutaneously without compromising effectiveness... Continue Reading

37,000 Patient Meta-Analyses Confirms Benefit of Dose Dense Therapy for Treatment of Early Stage Breast Cancer (April 30, 2019)

According to the National Cancer Institute the overall results of studies designed to compare dose dense therapy to every 3 week therapy support the use of dose-dense chemotherapy for the treatment of women with HER2-negative early stage breast cancer... Continue Reading

Dose Intense Chemotherapy Improves Survival When Used For Treatment of Early Stage Breast Cancer (April 8, 2019)

Giving chemotherapy drugs every two weeks instead of every three weeks reduces the risk of breast cancer recurrence and death in women undergoing adjuvant chemotherapy for early stage breast cancer. The analyses was performed by British physicians in... Continue Reading

Immunotherapy Offers New Hope in Triple Negative Breast Cancer (December 28, 2018)

Results from the Impassion 130 clinical trial published in the New England Journal of Medicine have demonstrated that immunotherapy can improve survival in breast cancer, especially in anti-programmed cell death ligand 1 (PD-1+) patients.  The results... Continue Reading

Herceptin Biosimilar Herzuma Approved for Certain Breast Cancer Indications (December 21, 2018)

The FDA has approved Celltrion and Teva’s Herzuma (trastuzumab-pkrb), a biosimilar trastuzumab referencing Herceptin, for the treatment of HER2-positive breast cancer. Herzuma is the second oncology biosimilar approval in the United States in the past... Continue Reading

Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer (December 19, 2018)

SAN ANTONIO — Patients with triple-negative breast cancer who delayed starting adjuvant chemotherapy for more than 30 days after surgery were at significantly higher risk for disease recurrence and death compared with those who started the treatment... Continue Reading

Trastuzumab emtansine Improves Treatment of Early Stage HER 2-positive Breast Cancer (December 12, 2018)

Adjuvant trastuzumab emtansine showed improved disease-free survival compared with trastuzumab in HER2-positive early breast cancer. Patients with HER 2-positive early stage breast cancer with residual disease who received adjuvant trastuzumab emtansine... Continue Reading

Oxybutynin Decreased Frequency of Hot Flashes, Improved Quality of Life for Breast Cancer Survivors (December 11, 2018)

Treatment with oxybutynin helped reduce the frequency and intensity of hot flashes for women who could not take hormone replacement, including breast cancer survivors, according to results of a trial presented at the 2018 San Antonio Breast Cancer Symposium,... Continue Reading

Choice of surgery may affect quality of life for young breast cancer survivors (December 10, 2018)

Even as more young women with breast cancer opt to have mastectomies, many experience a persistent decline in their sexual and psychosocial well-being following the procedure, as detailed in new research by Dana-Farber/Brigham and Women’s Cancer Center.... Continue Reading

Latest Breast Cancer News By Stage


Carcinoma In Situ Breast cancer

Sorry, there are no articles available for this cancer stage.

More Carcinoma In Situ Breast cancer

Inflammatory Breast Cancer

Sorry, there are no articles available for this cancer stage.

More Inflammatory Breast Cancer

Metastatic Breast Cancer

FDA approves new treatment for certain advanced or metastatic breast cancers (October 5, 2017)

The U.S. Food and Drug Administration today approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed... Continue Reading

FDA Grants Breakthrough Therapy Designation to DS-8201 for HER2-Positive Metastatic Breast Cancer (August 30, 2017)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), for the treatment of patients with HER2-positive, locally advanced or metastatic breast... Continue Reading

More Metastatic Breast Cancer

Recurrent Breast Cancer

Sorry, there are no articles available for this cancer stage.

More Recurrent Breast Cancer

Screening/Prevention Breast Cancer

Sorry, there are no articles available for this cancer stage.

More Screening/Prevention Breast Cancer

Stage I Node Negative Breast Cancer

Sorry, there are no articles available for this cancer stage.

More Stage I Node Negative Breast Cancer

Stages II-III Breast Cancer

Sorry, there are no articles available for this cancer stage.

More Stages II-III Breast Cancer

Supportive Care Breast Cancer

Sorry, there are no articles available for this cancer stage.

More Supportive Care Breast Cancer